Member Info for Hydr31

The Chinese wouldn’t be so daft as to buy foreign tests when they can make them at home. That’s just our government.

Personally expecting a lot more from the new sales teams. Think they need to be aiming for 50% plus growth in non Covid revenues. They have the products, they are growing the sales team into global reaching locations. We should see a real difference here if the right people are doing the right things.

In order to value it on a PE of 20 don’t we need to see evidence of growth

I think the 15 million ebitda needs to be growing at 20% per annum to support growth valuation

I have that at a 45% increase in non Covid revenues from around 14 million to 19 million in 2021.

Anybody else concur? This is very good as whilst we know Covid is set to continue dropping we are actually seeing significant gains in non Covid (sustainable) revenues.

To get to £54 we need to see a company that can produce £75 million in profit and is growing this at 20% plus year on year

Were way off that at the moment as most of our revenues are not sustainable into the future. But then for the long term investor over a ten year period this share could have legs. Really interested to see how we are developing the sustainable revenue streams as in my opinion that will be the driver for new highs. Also hoping we are going to use the cash to build out the company.

So I can understand why shorting can take prices temporarily lower than one would expect as I’m sat here with a holding that I’m quite happy to see half as I know if it happens it would be only temporary and it would be a hell of an opportunity to buy at stupid value. So I’m not investing my extra cash yet.

What I really don’t understand is why open shorts now, surely the risk of that net being wrong is quite high at £1. It can’t exactly fall far and when it finds support it will be a catapult back up as buying and shorters scramble to buy back. Why open a short for the last few percent, surely the smart shorting money was made by those who shorted at £4 and they’ve already closed to take long positions ?

Given what we spend on things like legionella and asbestos control ( where preventative death rates in the U.K. are usually less than 10 a year) I’m not surprised how much we spend on Covid and will spend going forward. In fact Covid now comes under the health and safety at work act so companies have a duty to protect their employees or face the consequences.

On the contrary, this share won’t rise till we put Covid behind us. There’s always going to be an underlying fear or revenues dwindling and poor sentiment whilst Covid remains the number one topic and revenue earner. Hoping the board give us something else to talk about next week.

It hit £1.12 in December. Revisiting it today. Let’s see if there is some support at this price

So much fear surrounding this stock. ‘End of the pandemic’ will only be a good thing for NCYT. They have made their cash and can pivot into other revenue streams. In fact the sooner they do and the market realises their existence isn’t reliant on Covid, the sooner we might reach a reasonable share price.

Sounds like the supply issues are behind us. Onwards and upwards from here.

Looks like a big cup and handle to me. We’re now in the handle. Volume has been declining as the price reduces. Price is looking nice for some buying now. Offering a really good dividend at these prices so hopefully we will see some positive volume and breakout soon…. Seems to take forever to move anywhere.

Boo are pandemic proof, they just pivot into what’s selling. That’s part of their business model. Last time it was joggers and masks next time it could be something else.

Another lockdown would be great for BOO as it forces all traffic online

Yes I’ve just popped back on here and amazed to see how the posters have changed. A lot seem quite happy to try to encourage the share price lower so if your a long term holder don’t worry too much, they are either shorting and will buy back in due course or want to get the best possible entry. Which is fine, short term price movements. Hell of an opportunity presenting itself here. 25% Rev growth, 9-9.5% ebitda delivers yet another year of earnings enhancement. And next year as the supply issues get sorted, debs beauty rolls out, aquisitions continue growing, BOO will start to look ridiculously undervalued.

Does anybody else think the chart is showing an inverted head and and shoulders pattern. We’ve just completed the second shoulder where it found support at circa £3. Neck line- the last two spikes up to circa £4.30. If so the reversal is on and it’s onwards and upwards from here.

I feel the markets over reacted here. We already knew there had been supply issues and I personally was expecting a downgrade to expectations on that basis. What I was hoping to see was stellar growth in revenues and market share which we have. Great opportunity to pick up some good value shares as in a years time with another 40% revenue growth and some resolutions to the supply crisis we’ll start seeing ebitda driving through. Plenty of cash, not a company that’s going to go bust or need a raise anytime soon. And growing in multiple countries across Europe at 40% a year with plenty of untapped potential.

Agree that is fantastic news… wish they had left it at that and wish they had given us some idea of the positive impact of having promate. Don’t understand why they are being so cryptic. As others say why do they have to mention a £3mill loss?! It’s peanuts in the grand scheme of things.

So the impact will be £3 million pounds?? Is that we will only have £3million in promate sales or is that the impact of not selling the other 9 tests will only be £3million so don’t worry about it.

Well this was always a bit of a gamble until FDA is approved. Prior to news we were being told there was a 90% chance of approval. Surely now the FDA have told us how to get approval we should stand a much better chance of approval within a 2-6month time period.

So why the big drop…. We are now in a better position than we were with regards to gaining approval.

Yes cash burn will continue and possibly funding needed once they have approval. But then once they have approval that becomes more insignificant.

I can only assume no news yet means no news yet. If it was negative news they would have issued an RNS. It was only a target date and the FDA work to their own calendars.